Forte Biosciences (FBRX) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases.

• Lead product candidate FB102 is an anti-CD122 monoclonal antibody targeting key immune pathways.

• FB102 has shown significant inhibition of T and NK cell proliferation and activation in preclinical studies.

• Positive Phase 1b data in celiac disease; ongoing trials in vitiligo and alopecia areata, with additional potential in type 1 diabetes.

Financial performance and metrics

• Aggregate offering price of securities will not exceed $500,000,000.

• Classified as a smaller reporting company, utilizing reduced disclosure requirements.

Use of proceeds and capital allocation

• Intended use of net proceeds from securities sales will be detailed in applicable prospectus supplements; broad discretion retained over allocation.